NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Expanded Access to RXDX-105 for Cancers With RET Alterations

No Longer AvailableN/A

Sponsor: Hoffmann-La Roche

Conditions: Cancers With RET Alterations

Interventions: RXDX-105

Countries: United States

Expanded access to RXDX-105 will be given to patients with cancers harboring RET alterations who have not received TKIs that target RET alterations, who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for RXDX-105.

Eligibility overview

Sex: ALL

Study type: EXPANDED_ACCESS

Eligibility criteria

Inclusion Criteria:

* Diagnosis of advanced cancer with RET alterations
* Unable to participate in an ongoing RXDX-105 clinical trial
* Willing and able to provide written, signed informed consent
* Medically suitable for treatment with RXDX-105

Exclusion Criteria:

* Prior treatment with a TKI that has activity against RET alterations
* Currently enrolled in an ongoing clinical study with any other investigational agent

Locations (1)

San Diego, California, United States